Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Ranging from simple browns to eye-popping oranges and greens, birds have some of the most unique colors in the animal kingdom ...